Journal of Hepatology

Papers
(The H4-Index of Journal of Hepatology is 106. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis3165
JHEP at a glance (October 2024)1925
MetALD accounts for a large part of what we call MASLD!1763
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connection1429
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)1355
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients1185
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi821
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t447
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis440
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis385
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats356
THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study313
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes311
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series305
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement304
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models285
SAT-151-YI The role of interleukin-8 in primary sclerosing cholangitisassociated immune cell dysregulation275
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension265
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial263
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma261
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone255
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele251
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis251
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis247
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis239
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland226
SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study224
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment222
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma221
SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population212
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria211
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid211
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality211
WED-483 Performance comparison of four hepatitis E antibodies detection methods210
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma206
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy203
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis202
THU-087 Herpesvirus viremia-cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein-Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure201
WED-439 Linkage of anti‐HCV reactive persons to HCV care and treatment services in Georgia198
WED-548 Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease193
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes193
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy183
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study182
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease181
LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hyp177
FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury172
OS-044 Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis172
THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease169
LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements168
FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decom164
OS-075 Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized clustercontrolled study (PADSTONE)157
FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure155
WED-086 Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients154
WED-153 A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care152
WED-083 Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma151
SAT-113 The intratumoral microbiome in HCC and its impact on treatment response149
WED-262 Prolonged cholestasis following hepatitis A : what lies beneath148
FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus146
SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to i146
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition145
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C142
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection138
WED-184 Assessment of impact of ascitic fluid polymorphonuclear count on development of spontaneous bacterial peritonitis and survival in patients with liver cirrhosis and ascites137
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance137
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure135
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results135
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus133
SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma132
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study131
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes130
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure129
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes128
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma128
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection128
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study128
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis127
THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis127
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis127
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study126
WED-367-YI Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity a125
WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian crosssectional study125
SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study124
FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD124
SAT-417-YI Sex disparities in response to low-carb, high-fat diet in MASLD124
WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunctionassociated steatotic liver disease and metabolic parameters121
WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness121
FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis118
FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD118
TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan’s vaccinated generations: a genome- wide association study117
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification117
FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom116
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States116
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide115
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”113
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April113
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis113
Sign up to EASL Campus: your open-access eLearning Hub112
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver111
Genomics on the road to functional cure of hepatitis B111
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease111
Reply to: “A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B’”110
Portal venous branches as an anatomic railroad for a gut-bile duct-axis109
Novel anti-cholestatic treatment strategies by combining inhibition of the Apical sodium-dependent bile acid transporter with stimulation of urinary bile salt excretion or lowering bile salt synthesis109
Automation of hepatitis C screening through electronic health record algorithm109
Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma108
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy107
Radiowater perfusion PETof the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade106
1.4632029533386